Arcus Biosciences focus is another anti PD-1 therapy.
https://arcusbio.com/pipeline/chart/
Peak sales estimated at USD $3.3B + USD $1.5B = USD $4.8B (see below)
( this is speculatively about 5-10% of the revenue opportunity for Zantrene in Cancer )
Currently in Phase 2 & 3
Market cap USD $2.5B
https://www.bloombergquint.com/busi...reet-touts-10-billion-opportunity-with-gilead
RACE will have 5 x Phase 2 trials underway by the end of 2022, not forgetting the track-record of historic approval for AML (Phase 3 / 4 history).
Industry news, page-160
-
- There are more pages in this discussion • 2,404 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.56 |
Change
-0.080(4.89%) |
Mkt cap ! $264.2M | |||
| Open | High | Low | Value | Volume |
| $1.62 | $1.63 | $1.54 | $166.5K | 104.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 9220 | $1.54 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 8015 | 2 |
View Market Depth
| Last trade - 14.53pm 07/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |